Brii Says Covid Therapy Shows 80% Cut to Hospitalization, Death.

The topline data readout from the National Institutes of Health-sponsored trial showed combined hospitalization and death risk cut by 80% for "non-hospitalized Covid-19 patients at high risk of clinical progression", the Chinese company said in a Hong Kong stock exchange filing Sunday. Brii Biosciences Ltd. said additional results of a late-stage study of a Covid-19 therapy confirmed a significantly reduced risk of death and hospitalization. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)